Forma To Play To Its Strengths WIth Genentech Deal
This article was originally published in Start Up
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
You may also be interested in...
In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.
Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.
The Wellcome Trust, the UK’s largest private funder of biomedical research, has hired industry veterans to run a new £200 million evergreen fund that will take full ownership of biotech start-ups and hold them with more patience than VCs can afford.